Jaw-Yuan Wang
Overview
Explore the profile of Jaw-Yuan Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
315
Citations
3777
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tsai H, Huang C, Chen Y, Su W, Chang T, Chen P, et al.
Medicina (Kaunas)
. 2023 Dec;
59(12).
PMID: 38138211
: Approximately 5-10% of all patients with metastatic colorectal cancer (mCRC) harbor a mutation. These patients exhibit distinct metastatic patterns, poor prognosis, and heterogenous survival outcomes. The findings from the...
12.
Chen Y, Huang C, Li C, Chang T, Su W, Chen P, et al.
World J Surg Oncol
. 2023 Dec;
21(1):378.
PMID: 38041083
Background: Systemic therapy is the standard treatment for unresectable colorectal cancer with liver metastasis (CRCLM). Transarterial chemoembolization with drug-eluting beads (DEB-TACE) is considered an effective treatment option for CRCLM. Few...
13.
Tsai H, Yeh Y, Chen P, Chang Y, Chen Y, Su W, et al.
Integr Cancer Ther
. 2023 Oct;
22:15347354231187153.
PMID: 37822243
Patients with cancer use low-molecular-weight fucoidan (LMF) as a supplement to therapy. However, most studies of LMF are or conducted using animals. Concurrent chemoradiotherapy (CCRT) is the gold standard for...
14.
Tsai H, Shi H, Chen Y, Huang C, Su W, Chang T, et al.
Am J Cancer Res
. 2023 Oct;
13(9):4039-4056.
PMID: 37818063
This study investigated the cost-effectiveness and quality of life (QoL) within 1 year of receiving mFOLOFX6 with or without a targeted drug (bevacizumab or ramucirumab) as second-line treatment among patients...
15.
Chen Y, Tsai H, Liang P, Wang J
Kaohsiung J Med Sci
. 2023 Aug;
39(10):1054-1055.
PMID: 37530671
No abstract available.
16.
Tsai H, Lin C, Sung Y, Chen S, Chen L, Jiang J, et al.
Br J Cancer
. 2023 Jul;
129(6):947-955.
PMID: 37488448
Absrtact: BACKGROUND: Patients treated with anti-epidermal growth factor receptor (anti-EGFR) will ultimately develop acquired resistance promoted by clonal selection, mainly the emergence of mutations in the MAPK pathway (mostly RAS...
17.
Kianpour M, Huang C, Vejvisithsakul P, Wang J, Li C, Shiao M, et al.
Int J Biol Macromol
. 2023 Jul;
248:125782.
PMID: 37481838
No abstract available.
18.
Chang Y, Chen C, Chang S, Chang Y, Lin B, Chen H, et al.
Nutrients
. 2023 Jul;
15(13).
PMID: 37447297
Malnutrition is a common problem in patients with metastatic colorectal cancer (mCRC) receiving targeted therapy plus chemotherapy, resulting in severe toxicity and decreased survival rates. This retrospective study employing propensity...
19.
Kianpour M, Huang C, Vejvisithsakul P, Wang J, Li C, Shiao M, et al.
Int J Biol Macromol
. 2023 Jun;
245:125510.
PMID: 37353120
The objectives were to identify the functional domains of a potential oncoprotein, cell migration inducing hyaluronidase 2 (CEMIP2), evaluate its expression levels and roles in colorectal cancer (CRC), and develop...
20.
Yeh Y, Tsai H, Chen Y, Su W, Chen P, Chang T, et al.
Oncol Res
. 2023 Jun;
30(2):65-76.
PMID: 37305327
The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients...